Uppal, Abhineet
Stern, Stacey
Thompson, John F.
Foshag, Leland
Mizzollo, Nicola
Nieweg, Omgo E.
Hoekstra, Harald J.
Roses, Daniel F.
Sondak, Vernon K.
Kashani-Sabet, Mohammed
Coventry, Brendon J.
Cochran, Alistair J.
Fujita, Manabu
Sim-Shin, Myung
Elashoff, David
Elashoff, Robert M.
Faries, Mark B.
Funding for this research was provided by:
National Cancer Institute (R01CA189163)
Article History
Received: 2 July 2019
First Online: 20 December 2019
Disclosures
: Mark B. Faries has served on advisory boards for Array Bioscience, Bristol-Myers Squibb, Novartis, Castle Bioscience and Pulse Bioscience, and is a consultant for Delcath Systems. Vernon K. Sondak has served on advisory boards for Merck, Bristol-Meyers Squibb, Novartis and Regeneron, as well as data safety monitor boards for Bristol-Meyers Squibb, Array Bioscience, Novartis, Polynoma and Pfizer. Alistair J. Cochran has received National Institutes of Health grant funding related to this manuscript. Abhineet Uppal, Stacey Stern, John F. Thompson, Leland Foshag, Nicola Mizzollo, Omgo E. Nieweg, Harald J. Hoekstra, Daniel F. Roses, Mohammed Kashani-Sabet, Brendon J. Coventry, Manabu Fujita, Myung Sim-Shin, David Elashoff, and Robert M. Elashoff have no conflicts of interest to declare.